Sign In
Buy PTIX
$0.410
+0 (+0%)
At Close: Jun 22, 2026
Protagenic Therapeutics Receives $3.1 Million from Recent Warrant Activity
09:15am, Wednesday, 21'st May 2025
NEW YORK, NY / ACCESS Newswire / May 21, 2025 / Protagenic Therapeutics, Inc. (Nasdaq:PTIX) (the "Company") announced today that warrant exchanges and exercises over the last four trading days have ge
Gold Gains Over 1%; Protagenic Therapeutics Shares Spike Higher
01:40pm, Monday, 19'th May 2025
U.S. stocks traded higher midway through trading, with the Dow Jones index gaining more than 150 points on Monday.
PTIX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Protagenic Therapeutics, Inc. Is Fair to Shareholders
11:15am, Monday, 19'th May 2025
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Protagenic Therapeutics, Inc. (NASDAQ: PTIX) and Phytanix Bio Inc. is fair to Protageni
NEW YORK, NY AND SANTA BARBARA, CA / ACCESS Newswire / May 19, 2025 / Protagenic Therapeutics, Inc. (Nasdaq:PTIX) (the "Company") and Phytanix Bio Inc. have entered into a definitive share exchange ag
Protagenic Therapeutics to Effect 1-for-14 Reverse Stock Split
04:00pm, Tuesday, 29'th Apr 2025
Measure taken to Comply with Nasdaq Rule 5550(a)(2) Regarding Minimum Bid Price NEW YORK, NY / ACCESS Newswire / April 29, 2025 / Protagenic Therapeutics, Inc. (Nasdaq:PTIX) ("Protagenic Therapeutics"
Protagenic Therapeutics Announces Closing of Private Placement for Aggregate Gross Proceeds of $1.275 Million
08:12am, Tuesday, 05'th Nov 2024
NEW YORK, NY / ACCESSWIRE / November 5, 2024 / Protagenic Therapeutics, Inc. (NASDAQ:PTIX) ("Protagenic Therapeutics" or the "Company"), a leader in biopharmaceutical innovation, announced today that
Protagenic Therapeutics Announces Pricing of Private Placement for Aggregate Gross Proceeds of $1.275 Million
09:27am, Tuesday, 29'th Oct 2024
NEW YORK, NY / ACCESSWIRE / October 29, 2024 / Protagenic Therapeutics, Inc. (Nasdaq:PTIX) ("Protagenic Therapeutics" or the "Company"), a leader in biopharmaceutical innovation, announced today it ha
Protagenic Therapeutics Completes Enrollment in Single Dose Portion of Phase 1 of Innovative Stress Disorder Trial
08:38am, Wednesday, 01'st May 2024
NEW YORK, NY / ACCESSWIRE / May 1, 2024 / Protagenic Therapeutics, Inc. (NASDAQ:PTIX), a leader in biopharmaceutical innovation, today announced the completion of enrollment in the single dose portion
Protagenic Therapeutics' Innovative Peptide PT00114 to be Highlighted at Boston Summit
08:42am, Wednesday, 17'th Apr 2024
Chief Operating Officer to Present Key Advances at Peptide Therapeutics Summit NEW YORK, NY / ACCESSWIRE / April 17, 2024 / Protagenic Therapeutics, Inc. (NASDAQ:PTIX), a pioneer in biopharmaceutical
Protagenic Therapeutics, Inc. (PTIX) Q4 2023 Earnings Call Transcript
09:32pm, Monday, 01'st Apr 2024
Protagenic Therapeutics, Inc. (PTIX) Q4 2023 Earnings Call Transcript
Protagenic Therapeutics Reports Fourth Quarter and Full Year 2023 Results
04:20pm, Monday, 01'st Apr 2024
Transitioned from Pre-Clinical to Clinical Stage company in FY 2023 Phase 1/2a trial, designed to assess both healthy volunteers and patients diagnosed with Treatment-Resistant Depression, PTSD or Gen
Next clinical progress update expected in April 2024 NEW YORK, NY / ACCESSWIRE / March 27, 2024 / Protagenic Therapeutics, Inc. (NASDAQ:PTIX), a leader in biopharmaceutical innovation, advances its mi
Protagenic Therapeutics Schedules First Q4 and FY 2023 Earnings Call
05:00pm, Monday, 25'th Mar 2024
Call Scheduled for Monday, April 1st, 2024, at 4:30 pm ET NEW YORK, NY / ACCESSWIRE / March 25, 2024 / Protagenic Therapeutics, Inc. (NASDAQ:PTIX), a biopharmaceutical innovator, announced that the Co
Protagenic Therapeutics Announces Resolution of Nasdaq Deficiency Notice
08:41am, Thursday, 21'st Mar 2024
NEW YORK, NY / ACCESSWIRE / March 21, 2024 / Protagenic Therapeutics, Inc. (NASDAQ:PTIX), a biopharmaceutical innovator, regained compliance with Nasdaq Listing Rule 5550(a)(2) as the closing bid pric
Company Anticipates Reporting Complete Phase I Single Dose Results in April NEW YORK, NY / ACCESSWIRE / February 13, 2024 / Protagenic Therapeutics, Inc. (NASDAQ:PTIX), a biopharmaceutical innovator,
